natgillin/translations-raw huggingface dataset:
Patients with pre-existing liver dysfunction, including chronic active hepatitis, have an increased frequency of liver function abnormalities during combination antiretroviral therapy and should be monitored according to standard practice.
Med kombiniranim protiretrovirusnim zdravljenjem so se pri bolnikih z že obstoječimi motnjami v delovanju jeter, vključno s kroničnim aktivnim hepatitisom, pogosteje pojavljale nepravilnosti v jetrnem delovanju in jih je bilo potrebno nadzirati po splošno uveljavljenih načelih.
Patients with pre-existing mild or moderate hepatic impairment should be monitored for signs and symptoms of hepatic dysfunction during treatment with Zinbryta.
Pri bolnikih z obstoječo blago ali zmerno okvaro jeter je treba med zdravljenjem z zdravilom Zinbryta spremljati pojav znakov in simptomov motnje delovanja jeter.
Patients with pre-existing risk factors
Bolniki s predhodno obstoječimi dejavniki tveganja
Patients with pre-existing severe neuropathy may be treated with Bortezomib Hospira only after careful risk/benefit assessment.
Bolnike z obstoječo hudo nevropatijo lahko zdravite z zdravilom Bortezomib Hospira šele po skrbnem pretehtanju razmerja koristi in tveganj.
Patients with pre-existing significant cardiac disease, such as congestive heart failure, coronary artery disease or arrhythmia, should be monitored for worsening of their cardiac condition, particularly during initiation of treatment with Betaferon.
Bolnike s pomembnimi srčnimi boleznimi, kot so kongestivna srčna odpoved, bolezen koronarnih arterij ali aritmija, je treba spremljati zaradi možnega poslabšanja srčne bolezni,zlasti na začetku zdravljenja z zdravilom Betaferon.
Patients with pre-existing tumours or growth hormone deficiency secondary to an intracranial lesion should be examined routinely for progression or recurrence of the underlying disease process.
Bolnike s predhodno ugotovljenim tumorjem ali s pomanjkanjem rastnega hormona, ki je posledica intrakranialne lezije, je treba rutinsko nadzirati glede napredovanja ali ponovitve osnovnega bolezenskega procesa.
Patients with previously treated light-chain (AL) Amyloidosis
Bolniki s predhodno zdravljeno amiloidozo lahkih verig (AL-amiloidoza)
Patients with previously treated light-chain (AL) Amyloidosis
Bolniki, s predhodno zdravljeno amiloidozo lahkih verig (AL amiloidoza)
Patients with primary aldosteronism generally will not respond to antihypertensive medicinal products acting through inhibition of the renin-angiotensin system.
Bolniki s primarnim aldosteronizmom se praviloma ne odzovejo na antihipertenzivna zdravila, ki zavirajo sistem renin-angiotenzin.
Patients with primary aldosteronism generally will not respond to antihypertensive medicinal products acting through inhibition of the renin-angiotensin system.
Pri bolnikih s primarnim aldosteronizmom zdravljenje z antihipertenzivi, ki zavirajo reninsko- angiotenzinski sistem, običajno ni učinkovito.
Patients with Primary Immunodeficiency Syndromes (PID), an inborn lack of antibodies.
Bolniki s primarnimi sindromi imunske pomanjkljivosti, prirojenim pomanjkanjem protiteles.
Patients with prior bevacizumab (n (%))
Bolniki, predhodno zdravljeni z bevacizumabom (n (%))
Patients with prior Cisplatin chemoradiotherapy
Bolnice s predhodno kemoterapijo s cisplatinom
Patients with Prior Cisplatin Chemoradiotherapy
Bolnice, ki so se predhodno zdravile s kemoradioterapijo s cisplatinom
Patients with prior cisplatin chemoradiotherapy
Bolniki s predhodno cisplatinsko kemoradioterapijo
Patients with prior exposure to cisplatin require a sustained treatment free interval to justify treatment with the combination (see section 5.1).
Pri bolnicah, ki so se predhodno zdravile s cisplatinom, mora preteči daljše obdobje brez zdravljenja, da se opraviči zdravljenje s kombinacijo (glejte poglavje 5.1).
Patients with prior ischaemic stroke
Bolniki s predhodno možgansko kapjo
Patients with prior OAB antimuscarinic therapy
Bolniki s predhodnim antimuskarinskim zdravljenjem PASM
Patients with prior OAB antimuscarinic therapy who discontinued due to insufficient effect
Bolniki s predhodnim antimuskarinskim zdravljenjem PASM, ki so to zdravljenje končali zaradi nezadostne učinkovitosti
Patients with prior stroke or TIA
Bolniki s predhodno možgansko kapjo ali TIA
Patients with prior treatment failure that included an integrase inhibitor (and integrase class resistance)
Bolniki s predhodnim neuspešnim zdravljenjem, ki je vključevalo zaviralec integraze (in odpornost na zdravila iz skupine zaviralcev integraze)
Patients with prior treatment failure, but not exposed to the integrase class
Bolniki z neuspešnim predhodnim zdravljenjem, ki niso bili izpostavljeni zdravilom iz skupine zaviralcev integraze
Patients with prior Whipple procedure
Bolniki s predhodno Whipplovo operacijo
Patients with prolonged QT at baseline (uncorrected > 440 msec), or severe bradycardia, sinus node dysfunction or second degree and third degree heart block in the absence of a pacemaker.
Bolniki z izhodiščnim podaljšanjem QT (nekorigirani QT > 440 ms) ali s hudo bradikardijo, disfunkcijo sinusnega vozla ali srčnim blokom 2. ali 3. stopnje brez srčnega spodbujevalnika.
Patients with psychotic disorders
IME ZDRAVILA
Patients with psychotic disorders should only be treated with dopamine agonists if the potential benefits outweigh the risks.
Bolnike s psihotičnimi motnjami zdravimo z agonisti dopamina le, kadar potencialna korist zdravljenja opravičuje tveganje.
Patients with psychotic disorders should only be treated with dopamine agonists if the potential benefits outweigh the risks.
Bolnike s psihotičnimi motnjami zdravimo z agonisti dopamina le, če pričakovana korist odtehta tveganje.
Patients with RA, PsA or AS who did not receive concomitant MTX had approximately 30% lower steady-state trough concentrations of golimumab than those who received golimumab with MTX.
Bolniki z revmatoidnim artritisom, psoriatičnim artritisom ali ankilozirajočim spondilitisom, ki sočasno niso prejemali metotreksata, so imeli približno 30 % manjše najnižje koncentracije golimumaba v stanju dinamičnega ravnovesja od tistih, ki so prejemali golimumab skupaj z metotreksatom.
Patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more Gadolinium enhancing lesions on brain MRI or a significant increase in T2 lesion load as compared to a previous recent MRI.
ali bolniki s hitro razvijajočo se hudo recidivno remitentno multiplo sklerozo, opredeljeno z dvema ali več zagoni, ki bolnika onesposobijo, v enem letu in z eno ali več lezijami, ki so pri magnetno resonančnem slikanju možganov vidne po okrepitvi z gadolinijem, ali znatnim povečanjem površine lezij T2 v primerjavi s predhodnim nedavnim magnetno resonančnim slikanjem.
Patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more Gadolinium enhancing lesions on brain MRI or a significant increase in T2 lesion load as compared to a previous recent MRI.
bolniki s hitro razvijajočo se hudo recidivno remitentno multiplo sklerozo, ki se kaže z 2 ali več recidivi prizadetosti v enem letu ter z 1 ali več lezijami, vidnimi z gadolinijem pri MRS možganov ali znatnim povečanjem površine lezij T2 v primerjavi s predhodnim nedavnim MRS.
Patients with rare glucose-galactose malabsorption should not take this medicine, as the formulation contains glucose.
Bolniki z redko malabsorpcijo glukoze/galaktoze ne smejo jemati tega zdravila, saj vsebuje glukozo.
Patients with rare hereditary conditions of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.
Bolniki z redko dedno motnjo neprenašanja galaktoze, laponsko obliko pomanjkanja laktaze ali malabsorpcijo glukoze/galaktoze tega zdravila ne smejo jemati.
Patients with rare hereditary problems of fructose intolerance or sucrase–isomaltase insufficiency should not take this medicinal product (see section 2).
Bolniki z redko dedno intoleranco za fruktozo ali s pomanjkanjem saharaze – izomaltaze ne smejo uporabljati tega zdravila (glejte poglavje 2).
Patients with rare hereditary problems of fructose intolerance should not take Levitra 10 mg orodispersible tablets.
Bolniki z redko dedno intoleranco za fruktozo ne smejo jemati tega zdravila.
Patients with rare hereditary problems of fructose intolerance should not take Onduarp.
Bolniki z redko dedno intoleranco za fruktozo ne smejo jemati zdravila Onduarp.
Patients with rare hereditary problems of fructose intolerance should not take Simponi.
Bolniki z redko dedno intoleranco za fruktozo ne smejo prejemati zdravila Simponi.
Patients with rare hereditary problems of fructose intolerance should not take Telmisartan Teva Pharma.
Bolniki z redko dedno intoleranco za fruktozo ne smejo jemati zdravila Telmisartan Teva Pharma.
Patients with rare hereditary problems of fructose intolerance should not take this medicinal product .
Bolniki z redko dedno intoleranco za fruktozo ne smejo jemati tega zdravila.
Patients with rare hereditary problems of fructose intolerance should not take this medicine.
Bolniki z dednim neprenašanjem fruktoze zdravila ne smejo jemati.
Patients with rare hereditary problems of fructose intolerance should not take this medicine.
Bolniki z redko dedno intoleranco na fruktozo ne smejo prejeti tega zdravila.
Patients with rare hereditary problems of fructose intolerance should not take this medicine.
Bolniki z redko dedno intoleranco za fruktozo ne smejo prejemati tega zdravila.
Patients with rare hereditary problems of fructose intolerance should not take Vivanza 10 mg orodispersible tablets.
Bolniki z redko dedno intoleranco za fruktozo ne smejo jemati tega zdravila.
Patients with rare hereditary problems of fructose intolerance should not use Prolia.
Bolniki z redko prirojeno motnjo intolerance za fruktozo ne smejo uporabljati zdravila Prolia.
Patients with rare hereditary problems of fructose intolerance should not use this medicinal product.
Bolniki z redko dedno intoleranco za fruktozo, ne smejo jemati tega zdravila.
Patients with rare hereditary problems of fructose intolerance should not use this medicine.
Bolniki z redko dedno intoleranco za fruktozo ne smejo jemati tega zdravila.
Patients with rare hereditary problems of fructose intolerance should not use XGEVA.
Bolniki z redko prirojeno motnjo intolerance za fruktozo ne smejo uporabljati zdravila XGEVA.
Patients with rare hereditary problems of fructose intolerance, glucose galactose malabsorption or sucrase- isomaltase insufficiency should not take this medicine.
Bolniki z redko dedno intoleranco za fruktozo, malabsorpcijo glukoze in galaktoze ali pomanjkanjem saharaza-izomaltaze ne smejo jemati tega zdravila.
Patients with rare hereditary problems of fructose intolerance, glucose malabsorption or sucrose- isomaltase insufficiency should not take this medicine.
Bolniki z redkimi prirojenimi motnjami, kot so intoleranca za fruktozo, malabsorpcija glukoze ali pomanjkanje saharaze-izomaltaze, ne smejo jemati tega zdravila.
Patients with rare hereditary problems of fructose intolerance, glucose- galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicinal product.
Bolniki z redkimi dednimi težavami intolerance za fruktozo, malabsorpcijo glukoze-galaktoze ali pomanjkanjem saharaze-izomaltaze tega zdravila ne smejo jemati.
Patients with rare hereditary problems of fructose intolerance, glucose- galactose malabsorption or sucrase-isomaltase insufficiency should not take this vaccine.
Bolniki z redko dedno intoleranco za fruktozo, malabsorpcijo glukoze/galaktoze ali pomanjkanjem saharoza-izomaltaze ne smejo prejeti tega cepiva.
Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take the oral solution.
Bolniki z redkimi prirojenimi motnjami, kot so intoleranca za fruktozo, malabsorpcija glukoze-galaktoze ali pomanjkanje saharaze-izomaltaze, ne smejo jemati peroralne raztopine.
Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine.
Bolniki z redkimi heriditarnimi težavami intolerance za fruktozo, malabsorpcije tipa glukoza- galaktoza ali insuficience saharaze-izomaltaze, tega zdravila ne smejo jemati.
Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine.
Bolniki z redkimi prirojenimi motnjami, kot so intoleranca za fruktozo, malabsorpcija glukoze-galaktoze ali pomanjkanje saharaze-izomaltaze, ne smejo jemati tega zdravila.
Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine.
Bolniki z redko dedno intoleranco za fruktozo, malabsorpcijo glukoze/galaktoze ali pomanjkanjem saharaza-izomaltaze ne smejo jemati tega zdravila.
Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine.
Bolniki z redko dedno intoleranco za fruktozo, malabsorpcijo glukoze/galaktoze ali pomanjkanjem saharoza­izomaltaze ne smejo jemati tega zdravila.
Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrose- isomaltase insufficiency should not take this medicine.
Bolniki z redko dedno intoleranco za fruktozo, malabsorpcijo glukoze/galaktoze ali pomanjkanjem saharoze-izomaltaze ne smejo jemati tega zdravila.
Patients with rare hereditary problems of galactase intolerance, Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.
Bolniki z redkimi dednimi težavami, kot so intoleranca za galaktozo, laponska oblika zmanjšane aktivnosti laktaze ali malabsorpcija glukoze/galaktoze, tega zdravila ne smejo jemati.
Patients with rare hereditary problems of galactose intolerance e.g. galactosaemia, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.
Bolniki z redkim, dednim neprenašanjem galaktoze, na primer galaktozemijo, s pomanjkanjem laktaze Lapp ali z malabsorpcijo glukoze-galaktoze zdravila ne smejo jemati.
Patients with rare hereditary problems of galactose intolerance e.g. galactosaemia, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.
Bolniki z redkim, dednim neprenašanjem galaktoze, na primer galaktozemijo, s pomanjkanjem laktaze Lapp ali z malabsorpcijo glukoze-galaktoze zdravila ne smejo jemati.
Patients with rare hereditary problems of galactose intolerance, lapp lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.
Bolniki z redko dedno intoleranco za galaktozo, laponsko obliko zmanjšane aktivnosti laktaze ali malabsorpcijo glukoze/galaktoze ne smejo jemati tega zdravila.
Patients with rare hereditary problems of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.
Bolniki z redkimi dednimi težavami neprenašanja galaktoze, laponsko obliko zmanjšane aktivnosti laktaze ali slabo absorpcijo glukoze-galaktoze ne smejo jemati tega zdravila.
Patients with rare hereditary problems of galactose intolerance, of the Lapp lactase deficiency or of glucose-galactose malabsorption should not take this medicine.
Bolniki z redko dedno intoleranco za galaktozo, laponsko obliko zmanjšane aktivnosti laktaze ali malabsorpcijo glukoze/galaktoze, ne smejo jemati tega zdravila.
Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose galactose malabsorption should not take this medicinal product.
Bolniki z redko dedno intoleranco za galaktozo, laponsko obliko zmanjšane aktivnosti laktaze ali malabsorpcijo glukoze/galaktoze ne smejo jemati tega zdravila.
Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose malabsorption should not take this medicine.
Bolniki z redko dedno obliko galaktozne intolerance, laponsko obliko zmanjšane aktivnosti laktaze ali malabsorpcijo glukoze-galaktoze, tega zdravila ne smejo jemati.
Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose- galactose malabsorption should not take Efient.
Bolniki z redko dedno intoleranco za galaktozo, laponsko obliko zmanjšane aktivnosti laktaze ali malabsorpcijo glukoze/galaktoze ne smejo jemati zdravila Efient.
Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose- galactose malabsorption should not take this medicinal product.
Bolniki z redko dedno intoleranco za galaktozo, laponsko obliko zmanjšane aktivnosti laktaze ali malabsorpcijo glukoze-galaktoze ne smejo jemati tega zdravila.
Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose- galactose malabsorption should not take this medicinal product.
Bolniki z redko dedno intoleranco za galaktozo, laponsko obliko zmanjšane aktivnosti laktaze ali malabsorpcijo glukoze/galaktoze ne smejo jemati tega zdravila.
Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose- galactose malabsorption should not take this medicinal product.
Bolniki z redko dedno intoleranco za galaktozo, laponsko obliko zmanjšane aktivnosti laktaze ali malabsorpcijo glukoze/galaktoze tega zdravila ne smejo jemati.
Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose- galactose malabsorption should not take this medicinal product..
Bolniki z redko dedno intoleranco za galaktozo, laponsko obliko zmanjšane aktivnosti laktaze ali malabsorpcijo glukoze-galaktoze ne smejo jemati tega zdravila.
Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose- galactose malabsorption should not take this medicine.
Bolniki z redkimi dednimi motnjami galaktozne intolerance, pomanjkanja Lapp laktaze ali malabsorpcije glukoze in galaktoze ne smejo prejemati tega zdravila.
Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose- galactose malabsorption should not take this medicine.
Bolniki z redkimi dednimi težavami, kot so intoleranca za galaktozo, laponska oblika zmanjšane aktivnosti laktaze ali malabsorpcija glukoze/galaktoze tega zdravila ne smejo jemati.
Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose- galactose malabsorption should not take this medicine.
Bolniki z redko dedno intoleranco na galaktozo, laponsko obliko zmanjšane aktivnosti laktaze ali malabsorpcijo glukoze/galaktoze, ne smejo jemati tega zdravila.
Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose- galactose malabsorption should not take this medicine.
Bolniki z redko dedno intoleranco za galaktozo, laponsko obliko zmanjšane aktivnosti laktaze ali malabsorpcijo glukoze/galaktoze ne smejo jemati tega zdravila.
Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.
Bolniki z redkimi podedovanimi težavami intolerance za galaktozo, s pomanjkanjem Lapp laktaze ali malabsorpcijo glukoze-galaktoze ne smejo jemati tega zdravila.
Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.
Bolniki z redkimi prirojenimi motnjami, kot so intolerance za galaktozo, laponska oblika zmanjšane aktivnosti laktaze ali malabsorpcija glukoze/galaktoze, ne smejo jemati tega zdravila.
Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.
Bolniki z redko dedno intoleranco za galaktozo, laponsko obliko zmanjšane aktivnosti laktaze ali malabsorpcije glukoze/galaktoze ne smejo jemati tega zdravila.
Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.
Bolniki z redko dedno intoleranco za galaktozo, laponskoobliko zmanjšane aktivnosti laktaze ali malabsorpcije glukoze/galaktoze ne smejo jemati tega zdravila.
Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.
Bolniki z redko dedno intoleranco za glukozo, laponsko obliko zmanjšane aktivnosti laktaze ali malabsorpcijo glukoze/galaktoze ne smejo jemati tega zdravila.
Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.
Bolniki z redkimi dednimi motnjami, kot so intoleranca za galaktozo, laponska oblika zmanjšane aktivnosti laktaze ali malabsorpcija glukoze-galaktoze, ne smejo jemati tega zdravila.
Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.
Bolniki z redko dedno inteleranco za galaktozo, laponsko obliko , zmanjšane aktivnosti laktaze ali malabsorbcije glukoze, galaktoze ne smejo jemati tega zdravila.
Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.
Bolniki z redko dedno intoleranco za fruktozo, intoleranco za galaktozo, kot je npr. galaktozemija, ali malabsorpcijo glukoze/galaktoze ne smejo jemati tega zdravila.
Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.
Bolniki z redko dedno intoleranco za galaktozo, laponsko obliko zmanjšane aktivnosti laktaze ali malabsorpcijo glukoze/galaktoze ne smejo jemati tega zdravila
Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.
Bolniki z redko dedno intoleranco za galaktozo, laponsko obliko zmanjšane aktivnosti laktaze ali okvarjeno absorpcijo glukoze ali galaktoze ne smejo jemati tega zdravila.
Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.
Bolniki z redko dedno intoleranco, laponska oblika zmanjšane aktivnosti laktaze ali malabsorpcijo glukoze/galaktoze ne smejo jemati tega zdravila.
Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.
Ne smejo ga jemati bolniki z redkimi dednimi boleznimi kot so intoleranca za galaktozo, laponska oblika zmanjšane aktivnosti laktaze ali malabsorpcija glukoze in galaktoze.
Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.
Ženske z redko dedno intoleranco za galaktozo, laponsko obliko zmanjšane aktivnosti laktaze ali malabsorpcijo glukoze/galaktoze ne smejo jemati tega zdravila.
Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption, should not take this medicine.
Zato ga ne smejo jemati bolniki z redkimi prirojenimi motnjami, kot so galaktozna intoleranca, laponska oblika zmanjšane aktivnosti laktaze ali malabsorbcija laktoze.
Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency, fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine.
Bolniki z redko dedno intoleranco za galaktozo, laponsko obliko zmanjšane aktivnosti laktaze, intoleranco za fruktozo, malabsorpcijo glukoze/galaktoze ali pomanjkanjem saharaze-izomaltaze ne smejo jemati tega zdravila.